Refine by
Oncology Target Equipment & Supplies
8 equipment items found
Manufactured by:Tempus based inChicago, ILLINOIS (USA)
Targeted panel designed to detect actionable oncological targets in plasma. ...
Manufactured by:Precirix based inBrussels, BELGIUM
Our lead product candidate, CAM-H2, consists of an HER2-targeting single-domain antibody linked to iodine-131. This targeted radioligand therapy is being developed for the treatment of patients with metastatic HER2-positive cancer indications, such as breast and gastric adenocarcinoma. In addition to the company’s lead program, two product candidates for ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CD71 is an excellent “internalizer,” which has the potential to efficiently deliver toxin to tumor cells. Historically, CD71 has not been widely pursued as a target given its expression on normal tissues and potential for causing toxicities. CytomX presented initial Phase 1 data at ASCO 2020 validating CD71 as a first-in-class oncology ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
Orion’s platform and science unlocks the therapeutic potential of GPCR targets across a broad range of medical needs. Our approach allows us to focus our discovery and development efforts across peptide and protein GPCR subfamilies, generating a diversified pipeline of potential first-in-class/best-in-class antagonist and agonist therapies against high-value ...
by:Sibylla Biotech S.p.A. based inVerona, ITALY
We are currently working on the hit-to-lead process for KRAS and Cyclin D1 (CCND1) proteins in the biology ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the entire GPCR family, and many valuable receptors remain undrugged. In particular, GPCRs whose natural ligands are large peptides or small proteins are ...
by:Taiwan Liposome Company, Ltd. (TLC) based inNangang Distric, TAIWAN
TLC is using antibodies and antibody fragments attached to lipid encapsulated drugs to develop more effective therapies in oncology. These antibody-linked nanomedicines actively target specific tissues using binding interactions between a specific antibody and a target antigen on the surface of a particular cell type. Compared with passively ...
Manufactured by:Mablink Bioscience based inLyon, FRANCE
Antibody–drug conjugates (ADCs) are a unique class of targeted immuno-oncology therapeutics that combine the tumor-targeting selectivity, stability, and favorable pharmacokinetic profile of monoclonal antibodies, with the potent antitumor activity of cytotoxic drugs. The ultimate goal of ADCs is to increase the therapeutic index of potent ...